A
Alexandra Blatt
Researcher at Rambam Health Care Campus
Publications - 6
Citations - 293
Alexandra Blatt is an academic researcher from Rambam Health Care Campus. The author has contributed to research in topics: Antibody & Infliximab. The author has an hindex of 5, co-authored 6 publications receiving 252 citations.
Papers
More filters
Journal ArticleDOI
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
Yoav Mazor,Yoav Mazor,Ronit Almog,Ronit Almog,Uri Kopylov,D. Ben Hur,Alexandra Blatt,Aviva Dahan,Matti Waterman,Matti Waterman,Shomron Ben-Horin,Yehuda Chowers,Yehuda Chowers +12 more
TL;DR: Adalimumab is an effective treatment for Crohn's disease and anti‐adalimumab antibodies (AAA) and low trough serum drug concentrations have been implicated as pre‐disposing factors for treatment failure.
Journal ArticleDOI
The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans
Einat Gochman,Jamal Mahajna,Pessia Shenzer,Aviva Dahan,Alexandra Blatt,Rami Elyakim,Abraham Z. Reznick +6 more
TL;DR: Findings that in inflammation and colon cancer in humans, iNOS expression and tyrosine nitration may be an indicator of cancer development and progression are strengthened.
Journal ArticleDOI
Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
Haggai Bar-Yoseph,Sigal Pressman,Alexandra Blatt,Shiran Gerassy Vainberg,N Maimon,Elina Starosvetsky,Bella Ungar,Shomron Ben-Horin,Shai S. Shen-Orr,Yehuda Chowers,Yehuda Chowers +10 more
TL;DR: It is proposed that infliximab-TNF complexes formed in the intestine are endocytosed by and activate innate immune cells, which increase expression of IL1B and TNF and production of antibodies against the drug complex.
Journal ArticleDOI
The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression.
Preeti Singh,Alexandra Blatt,Sari Feld,Yaniv Zohar,Esraa Saadi,Liza Barki-Harrington,Edward Hammond,Neta Ilan,Israel Vlodavsky,Yehuda Chowers,Elizabeth E. Half +10 more
TL;DR: Evidence is provided that heparanase down regulates the expression of p21 (WAF1/CIP1), a cyclin-dependent kinase inhibitor that attenuates the cell cycle, which adds a novel feature for the emerging pro-tumorigenic properties of heParanase.
Journal ArticleDOI
Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
Roni Weisshof,Bella Ungar,Alexandra Blatt,Aviva Dahan,Sigal Pressman,Matti Waterman,Matti Waterman,Uri Kopylov,Shomron Ben-Horin,Shomron Ben-Horin,Yehuda Chowers,Yehuda Chowers +11 more
TL;DR: Detection of neutralizing antibody activity was superior to antibody quantization by enzyme-linked immunosorbent assay with respect to correlation with clinical LOR, and for prediction of subsequent LOR in patients with inflammatory bowel disease.